BML Capital Management LLC Makes New $2.02 Million Investment in Outset Medical, Inc. $OM

Key Points

• BML Capital Management purchased 543,180 shares of Outset Medical (about $2.02M) in the fourth quarter, making the position roughly 1.7% of BML's portfolio and its ninth-largest holding; BML now owns about 2.99% of Outset per the SEC filing.
• Outset Medical currently has a market cap of $88.39 million, a one‑year trading range of $3.00–$21.98 and a negative P/E, while analyst coverage is mixed with an average rating of "Moderate Buy" and an average price target of $10.00.
• Several other institutional investors also increased exposure to OM recently — notably Millennium Management and Alyeska Investment Group — signaling broader institutional buying activity.

BML Capital Management LLC purchased a new position in shares of Outset Medical, Inc. (NASDAQ:OM - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 543,180 shares of the company's stock, valued at approximately $2,015,000. Outset Medical accounts for about 1.7% of BML Capital Management LLC's investment portfolio, making the stock its 9th largest holding. BML Capital Management LLC owned about 2.99% of Outset Medical as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of OM. Millennium Management LLC increased its stake in Outset Medical by 165.8% during the third quarter. Millennium Management LLC now owns 421,409 shares of the company's stock worth $5,950,000 after purchasing an additional 262,874 shares during the period. Alyeska Investment Group L.P. increased its stake in Outset Medical by 10.2% during the third quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company's stock worth $22,798,000 after purchasing an additional 150,000 shares during the period. Balyasny Asset Management L.P. purchased a new stake in Outset Medical during the second quarter worth about $2,750,000. Bank of America Corp DE increased its stake in Outset Medical by 37,130.1% during the second quarter. Bank of America Corp DE now owns 135,890 shares of the company's stock worth $2,610,000 after purchasing an additional 135,525 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in Outset Medical by 34.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 508,414 shares of the company's stock worth $1,886,000 after purchasing an additional 131,381 shares during the period.

Outset Medical Stock Performance

Shares of Outset Medical stock opened at $4.77 on Wednesday. Outset Medical, Inc. has a one year low of $3.00 and a one year high of $21.98. The company has a market cap of $88.39 million, a PE ratio of -0.70 and a beta of 1.92. The company has a debt-to-equity ratio of 0.76, a quick ratio of 5.40 and a current ratio of 6.67. The business has a 50-day simple moving average of $3.84 and a 200-day simple moving average of $5.37.

Wall Street Analyst Weigh In

OM has been the subject of a number of analyst reports. Wall Street Zen downgraded Outset Medical from a "hold" rating to a "sell" rating in a research report on Saturday, April 11th. Stifel Nicolaus lowered their price objective on Outset Medical from $14.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, January 7th. BTIG Research lowered their price objective on Outset Medical from $17.00 to $15.00 and set a "buy" rating for the company in a research report on Thursday, February 12th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Outset Medical in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $10.00.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company's flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo's modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.

Want to see what other hedge funds are holding OM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Outset Medical, Inc. (NASDAQ:OM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.